Literature DB >> 16682084

Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.

Susan J Baigent1, Lorraine P Smith, Venugopal K Nair, Richard J W Currie.   

Abstract

Marek's disease is an economically important lymphoid neoplasm of chickens, caused by oncogenic strains of Marek's disease herpesvirus. The disease can be successfully controlled by vaccination with attenuated or non-pathogenic MDV strains. However, vaccine failures do occur as field strains continue to evolve towards pathotypes of greater virulence, and this evolution is likely to be driven by the vaccines themselves. Two general strategies can be considered to improve protection by vaccination. Firstly by the development of novel vaccines, and secondly by maximizing the potential of existing vaccines. This second goal requires investigation of optimal timing and vaccine delivery route, and optimal vaccination regimes for different breeds of chick. Accurate quantitation of Marek's disease vaccine virus in vaccinated chicks will contribute significantly to our understanding of vaccinal protection. We recently developed a real-time polymerase chain reaction (PCR) assay for quantitation of CVI988 vaccine virus in the feather tips, a rich source of viral DNA which can easily be sampled in a non-invasive manner. This PCR test is now used commercially to confirm the successful vaccination of chicks. We have also used the PCR to examine various aspects of vaccination in experimental chicks and commercial chicks with a view to determining how vaccine level in feathers correlates with protection against challenge, and for identifying optimal timing and vaccine delivery route, and optimal vaccination regimes for different breeds of chick. In this article we review some aspects of the current vaccinal control of Marek's disease, before highlighting some of the problems associated with current vaccines and vaccination strategies, and the challenges for the future. We go on to discuss the development and use of our real-time PCR feather test, its current applications and potential opportunities in Marek's disease vaccine research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682084     DOI: 10.1016/j.vetimm.2006.03.014

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  23 in total

1.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Revaccination with Marek's disease vaccines induces productive infection and superior immunity.

Authors:  Changxin Wu; Junji Gan; Qiao Jin; Chuangfu Chen; Ping Liang; Yantao Wu; Xuefen Liu; Li Ma; Fred Davison
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

3.  Integrated analyses of genome-wide DNA occupancy and expression profiling identify key genes and pathways involved in cellular transformation by a Marek's disease virus oncoprotein, Meq.

Authors:  Sugalesini Subramaniam; John Johnston; Likit Preeyanon; C Titus Brown; Hsing-Jien Kung; Hans H Cheng
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

4.  Biomarker discovery in animal health and disease: the application of post-genomic technologies.

Authors:  Rowan E Moore; Jennifer Kirwan; Mary K Doherty; Phillip D Whitfield
Journal:  Biomark Insights       Date:  2007-07-10

5.  A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation.

Authors:  Keith Jarosinski; Lisa Kattenhorn; Benedikt Kaufer; Hidde Ploegh; Nikolaus Osterrieder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-04       Impact factor: 11.205

6.  Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cells.

Authors:  Annemarie T Engel; Ramesh K Selvaraj; Jeremy P Kamil; Nikolaus Osterrieder; Benedikt B Kaufer
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

7.  Dual infection and superinfection inhibition of epithelial skin cells by two alphaherpesviruses co-occur in the natural host.

Authors:  Keith W Jarosinski
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

8.  Modelling Marek's disease virus (MDV) infection: parameter estimates for mortality rate and infectiousness.

Authors:  Katherine E Atkins; Andrew F Read; Nicholas J Savill; Katrin G Renz; Stephen W Walkden-Brown; Mark E J Woolhouse
Journal:  BMC Vet Res       Date:  2011-11-11       Impact factor: 2.741

9.  Mapping QTL affecting resistance to Marek's disease in an F6 advanced intercross population of commercial layer chickens.

Authors:  Eliyahu M Heifetz; Janet E Fulton; Neil P O'Sullivan; James A Arthur; Hans Cheng; Jing Wang; Morris Soller; Jack C M Dekkers
Journal:  BMC Genomics       Date:  2009-01-14       Impact factor: 3.969

10.  Expression pattern of genes of RLR-mediated antiviral pathway in different-breed chicken response to Marek's disease virus infection.

Authors:  Ze-Qing Feng; Ting Lian; Yong Huang; Qing Zhu; Yi-Ping Liu
Journal:  Biomed Res Int       Date:  2013-04-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.